Connor, Clark & Lunn Investment Management (CC&L)
LUMO

Connor, Clark & Lunn Investment Management (CC&L)’s Lumos Pharma, Inc. Common Stock LUMO Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio LUMO Stock Details LUMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-33,367
Closed -$295K – 1466
2022
Q3 		$295K Hold
33,367
– – ﹤0.01% 927
2022
Q2 		$257K Hold
33,367
– – ﹤0.01% 896
2022
Q1 		$315K Sell
33,367
-60
-0.2% -$536 ﹤0.01% 863
2021
Q4 		$232K Hold
33,427
– – ﹤0.01% 947
2021
Q3 		$318K Buy
33,427
+1,489
+5% +$14K ﹤0.01% 861
2021
Q2 		$317K Sell
31,938
-1,355
-4% -$15.1K ﹤0.01% 856
2021
Q1 		$390K Buy
33,293
+2,042
+7% +$34.3K ﹤0.01% 822
2020
Q4 		$1.12M Sell
31,251
-727
-2% -$12.5K 0.01% 613
2020
Q3 		$442K Sell
31,978
-4,553
-12% -$68.1K ﹤0.01% 742
2020
Q2 		$602K Sell
36,531
-499
-1% -$5.94K ﹤0.01% 717
2020
Q1 		$315K Sell
37,030
-4,559
-11% -$63.7K ﹤0.01% 791
2019
Q4 		$947K Sell
41,589
-3,133
-7% -$44.7K 0.01% 555
2019
Q3 		$640K Sell
44,722
-20,065
-31% -$294K ﹤0.01% 623
2019
Q2 		$863K Sell
64,787
-5,002
-7% -$75.6K 0.01% 604
2019
Q1 		$1.21M Sell
69,789
-611
-0.9% -$9.11K 0.01% 493
2018
Q4 		$963K Sell
70,400
-3,409
-5% -$60K 0.01% 562
2018
Q3 		$1.59M Sell
73,809
-1,067
-1% -$32.4K 0.01% 481
2018
Q2 		$3.21M Buy
74,876
+12,739
+21% +$584K 0.02% 385
2018
Q1 		$4.05M Buy
62,137
+11,897
+24% +$843K 0.02% 313
2017
Q4 		$3.67M Buy
50,240
+4,108
+9% +$340K 0.02% 330
2017
Q3 		$4.23M Buy
46,132
+32,856
+247% +$2.52M 0.03% 321
2017
Q2 		$878K Buy
13,276
+10,212
+333% +$1.26M 0.01% 520
2017
Q1 		$665K Sell
3,064
-1,447
-32% -$207K ﹤0.01% 575
2016
Q4 		$417K Sell
4,511
-456
-9% -$51.4K ﹤0.01% 638
2016
Q3 		$671K Buy
4,967
+1,811
+57% +$180K ﹤0.01% 531
2016
Q2 		$320K Buy
+3,156
New +$391K ﹤0.01% 663

Other funds holding LUMO

Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.4% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s LUMO Position: Q4 2022 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Lumos Pharma, Inc. Common Stock (LUMO) in Q4 2022, closing a stake of 33,367 shares — an estimated $295K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in LUMO in Q2 2016 and held it in 26 quarters. The position peaked at $4.23M in Q3 2017. 37 funds tracked by Wall St. Rank hold LUMO as of Q4 2022.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Lumos Pharma, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 33,367 Lumos Pharma, Inc. Common Stock shares in Q4 2022, an estimated $295K.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Lumos Pharma, Inc. Common Stock in Q2 2016 and held it in 26 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Lumos Pharma, Inc. Common Stock position peaked at $4.23M in Q3 2017.
  • 37 funds tracked by Wall St. Rank held Lumos Pharma, Inc. Common Stock as of Q4 2022.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q4 2022, filed 10 Feb 2023.